Radcliffe Cardiology

SUMMIT at #AHA26: tirzepatide reduced LA volume and RV mass vs placebo in obesity-related HFpEF, with LA volume change linked to KCCQ.

Dr Milton Packer on the mechanisms and what it means for practice 🎥 radc.life/UhGEwtcI

#ScientificSessions26 #HFpEF

Not in Chicago for #ScientificSessions26? Join us online.
Our AHA 2026 Late-Breaking Collection is live, with short expert takes on the trials everyone is talking about.

• ZEUS: Ziltivekimab lowers hsCRP by 64% but does not reduce MACE, with Harriette Van Spall and Paul M Ridker
• Lp(a)HORIZON: Substantial Lp(a) lowering but an HR of 1.02, why? With Harriette Van Spall and Steven E Nissen
• OCEANIC-STROKE: Outcomes across cardiovascular risk groups with Mukul Sharma

More interviews from booth #3107 are landing throughout the day. Watch them here:

👉 radc.life/zlfKqrk9

Follow Radcliffe Cardiology so you don't miss the latest from AHA 2026.

American Heart Association
#Cardiology #CardiovascularMedicine #CardiovascularScience #ClinicalTrials #HeartHealth

What if access to echo expertise did not depend on having the specialist in the room? From #ScientificSessions26 in Chicago, Dr Alexis Kofi Okoh discusses INSIGHT: competency-based training + AI-assisted echo acquisition + remote cardiologist interpretation. Watch the interview here 🔗radc.life/UVn0AGMl

@AHAScience @American_Heart
#INSIGHT #Echocardiography #AIinHealthcare #CardiacImaging #DigitalHealth #Cardiology #CardiovascularCare

This is an independent interview produced by Radcliffe Cardiology.

Welcome to day two at #ScientificSessions26 in Chicago.
We had some great conversations at our booth yesterday, and today we're back with another packed line-up.

If you're at AHA 2026, come and find us at Booth #3107. We'd love to hear from you!

American Heart Association
#ScientificSessions26 #Cardiology #CardiovascularMedicine #CardiovascularScience #ClinicalTrials #HeartHealth

🧠 Patients at higher vascular risk may also be more vulnerable to bleeding. Did baseline risk modify the #OCEANICSTROKE findings?
Ischaemic stroke HR:
🟢 Low: 0.62
🟡 Intermediate: 0.89
🔴 High: 0.73
↔️ P-interaction: 0.58

🩸 Major bleeding
↔️ P-interaction: 0.60
The exploratory analysis found no significant evidence that efficacy or major bleeding outcomes differed by Framingham risk category. Estimates in the smaller low- and intermediate-risk groups remain imprecise.
In our #AHA26 interview, Prof Mukul Sharma explores what this consistency could mean when balancing recurrent ischaemic stroke against bleeding risk in secondary prevention.

🎥 radc.life/7loa6Q5I
#Stroke #FXIa #SecondaryStrokePrevention #CardioTwitter